Patient support materials available - click here
Intended for UK healthcare professionals
Soprobec contains beclometasone dipropionate in a pressurised inhalation solution.
Maintenance treatment of asthma when the use of pressurised metered dose inhaler is appropriate. See SmPC for full details.
Starting dose should be adjusted to severity of disease, then adjusted until control is achieved, then titrated to lowest dose at which effective asthma control is maintained.
Adults (including the elderly): Usual starting dose is 200 mcg twice daily. In severe cases this may be increased up to 600-800 mcg daily. (Soprobec 250 mcg only: usually 1000 mcg daily, which may be increased to 2000 mcg daily). Dose may be reduced when the patient’s asthma has stabilised. Total daily dose should be administered as 2-4 divided doses.
Children: Usual starting dose is 100 mcg twice daily. Depending on asthma severity, this may be increased up to 400 mcg administered in in 2-4 divided doses. Soprobec 200 mcg and 250 mcg are not recommended for children.
The VolumaticTM spacer device must always be used for:
Soprobec demonstration video
Use to facilitate Soprobec device training. Can also be accessed by patients prescribed Soprobec from the patient website.
It’s just like Clenil®…3
Available in four strengths:
50 mcg, 100 mcg, 200 mcg and 250 mcg
The cost of Soprobec is 35% lower than
the equivalent Clenil® pack and strength1,2
What could this cost saving representfor the NHS?
The NHS could have saved approximately £15.4m in annual drug acquisition costs in the year to December 2023 if they had prescribed Soprobec by brand instead of Clenil® Modulite®2
A local health economy spending £699,000 on Clenil® Modulite® in the year to December 2023 could have saved £245,000 if they had prescribed Soprobec by brand2
Think Soprobec for all pMDI beclometasone dipropionate prescriptions
Prescribe Soprobec by brand to ensure:
Your patients get the device prescribed
You get the full cost savings for your practice
Your health economy gets the full cost savings
Soprobec offers total commitment to the needs of
the patient, prescriber and pharmacist
Soprobec provides a four-strength dosage range, with equivalent user experience, combined with substantial cost savings vs. Clenil®1-6
With its four dosage options,4 Soprobec offers prescribers an equivalent product that can be titrated as required for appropriate patients, and enables pharmacists to stock just one brand for all possible doses.
Glenmark can provide financial savings estimates for your local health economy. To find out how much your health authority could save, click on the link below to arrange an appointment.
The Glenmark planned approach –
commitment to supply readiness
We are committed to ensuring Soprobec is available
to order from the moment usage is agreed:
Primary Care Organisation (PCO) agrees to move from Clenil® to Soprobec
Glenmark head office informed by representative
Glenmark head office alerts wholesalers
Wholesalers ensure they stock sufficient supply of Soprobec for PCO
Soprobec supply -Ready to meet your needs
When you prescribe Soprobec by brand, your patients get an equivalent user experience to Clenil®.3-6 They will also have access to clear information and support to ensure they take their medication correctly.
The patient tear-off pad allows healthcare professionals to give patients a sheet with information about Soprobec and how to use their inhaler. Click here to download
The Soprobec dedicated patient website containsinformation and support for
The Soprobec dedicated patient website contains information and support for patients who have been prescribed Soprobec, with guidance on how to use their inhaler, FAQs and links to trusted websites. Click here to view.
Soprobec® is a registered trademark of Glenmark Pharmaceuticals Europe Limited.
Clenil® Modulite® are registered trademarks of Chiesi Limited.
VolumaticTM is a trademark of the GlaxoSmithKline group of companies.
PIP codes: Soprobec 50 mcg/actuation - 4098620,
Soprobec 100 mcg/actuation- 4098638,
Soprobec 200 mcg/actuation - 4098646,
Soprobec 250 mcg/actuation - 4098653.
© 2024 Glenmark Pharmaceuticals Europe Ltd. All rights reserved. Date of preparation: April 2024 PP-UK-SOP-0035 V12
